Scott J. Hecker
Geen lopende functies
Profiel
Scott J.
Hecker was the founder of Rempex Pharmaceuticals, Inc. founded in 2011, where he held the title of Vice President-Chemistry.
He also held the title of Vice President-Chemistry at MPEX Pharmaceuticals, Inc. Dr. Hecker's former jobs include being a Principal at Pfizer Inc., Vice President-Chemistry at Essential Therapeutics, Inc. from 1993 to 2003, Vice President-Chemistry at Metabasis Therapeutics, Inc. from 2003 to 2009, and Vice President-Chemistry at MPEX Pharmaceuticals, Inc. Dr. Hecker's education history includes a doctorate from the University of California, Berkeley and an undergraduate degree from Wesleyan University.
Eerdere bekende functies van Scott J. Hecker
| Bedrijven | Functie | Einde |
|---|---|---|
Rempex Pharmaceuticals, Inc.
 Rempex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA. | Founder | 01-12-2013 |
Metabasis Therapeutics, Inc.
 Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | Corporate Officer/Principal | 01-01-2009 |
Essential Therapeutics, Inc.
 Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections | Corporate Officer/Principal | 01-01-2003 |
| PFIZER, INC. | Corporate Officer/Principal | - |
MPEX Pharmaceuticals, Inc.
 MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Opleiding van Scott J. Hecker
| University of California, Berkeley | Doctorate Degree |
| Wesleyan University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Essential Therapeutics, Inc.
Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections | Health Technology |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | Health Technology |
MPEX Pharmaceuticals, Inc.
MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Commercial Services |
Rempex Pharmaceuticals, Inc.
Rempex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA. | Health Technology |
